Syndax Pharmaceuticals In... (SNDX)
NASDAQ: SNDX
· Real-Time Price · USD
9.21
0.02 (0.22%)
At close: Jun 24, 2025, 3:59 PM
0.22% (1D)
| Bid | 9.2 |
| Market Cap | 792.07M |
| Revenue (ttm) | 43.72M |
| Net Income (ttm) | -331.2M |
| EPS (ttm) | -3.85 |
| PE Ratio (ttm) | -2.39 |
| Forward PE | -3.55 |
| Analyst | Buy |
| Ask | 9.44 |
| Volume | 2,388,867 |
| Avg. Volume (20D) | 2,208,324 |
| Open | 9.30 |
| Previous Close | 9.19 |
| Day's Range | 8.94 - 9.47 |
| 52-Week Range | 8.58 - 25.07 |
| Beta | 0.74 |
About SNDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SNDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SNDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Syndax Pharmaceuticals Inc. is scheduled to release its earnings on Jul 31, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+7.47%
Syndax Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
3 months ago
-1.02%
Syndax Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its EPS and sales estimate.
1 month ago · seekingalpha.com
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Direct...
